Goldman Sachs Group Inc Cassava Sciences Inc Transaction History

Goldman Sachs Group Inc

  • $613 Billion
  • Q4 2024

A detailed history of Goldman Sachs Group Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 278,909 shares of SAVA stock, worth $753,054. This represents 0.0% of its overall portfolio holdings.

Number of Shares
278,909
Previous 152,939 82.37%
Holding current value
$753,054
Previous $4.5 Million 85.38%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025
BUY
$2.29 - $32.18 $288,471 - $4.05 Million
125,970 Added 82.37%
278,909 $658,000
Q3 2024

Nov 14, 2024
BUY
$9.57 - $35.08 $647,831 - $2.37 Million
67,694 Added 79.41%
152,939 $4.5 Million
Q2 2024

Aug 13, 2024
BUY
$12.35 - $26.11 $400,312 - $846,329
32,414 Added 61.35%
85,245 $1.05 Million
Q1 2024

May 15, 2024
SELL
$18.44 - $26.41 $2.01 Million - $2.87 Million
-108,828 Reduced 67.32%
52,831 $1.07 Million
Q4 2023

Feb 13, 2024
BUY
$12.64 - $30.11 $1.37 Million - $3.27 Million
108,456 Added 203.85%
161,659 $3.64 Million
Q3 2023

May 14, 2024
SELL
$16.64 - $25.32 $1.8 Million - $2.75 Million
-108,456 Reduced 67.09%
53,203 $885,000
Q3 2023

Nov 14, 2023
SELL
$16.64 - $25.32 $204,954 - $311,866
-12,317 Reduced 18.8%
53,203 $885,000
Q2 2023

May 14, 2024
BUY
$21.59 - $27.88 $43,331 - $55,955
2,007 Added 3.16%
65,520 $1.61 Million
Q2 2023

Aug 14, 2023
BUY
$21.59 - $27.88 $43,331 - $55,955
2,007 Added 3.16%
65,520 $1.61 Million
Q1 2023

May 14, 2024
SELL
$23.46 - $36.44 $2.25 Million - $3.49 Million
-95,734 Reduced 60.12%
63,513 $1.53 Million
Q1 2023

May 11, 2023
SELL
$23.46 - $36.44 $2.25 Million - $3.49 Million
-95,734 Reduced 60.12%
63,513 $1.53 Million
Q4 2022

May 14, 2024
BUY
$27.82 - $44.16 $2.29 Million - $3.64 Million
82,452 Added 107.37%
159,247 $4.7 Million
Q4 2022

Feb 13, 2023
BUY
$27.82 - $44.16 $2.29 Million - $3.64 Million
82,452 Added 107.37%
159,247 $4.7 Million
Q3 2022

May 14, 2024
BUY
$16.33 - $51.06 $640,756 - $2 Million
39,238 Added 104.48%
76,795 $3.21 Million
Q3 2022

Nov 10, 2022
BUY
$16.33 - $51.06 $640,756 - $2 Million
39,238 Added 104.48%
76,795 $3.21 Million
Q2 2022

May 14, 2024
SELL
$17.22 - $38.47 $2.14 Million - $4.77 Million
-124,102 Reduced 76.77%
37,557 $1.06 Million
Q2 2022

Aug 15, 2022
SELL
$17.22 - $38.47 $28,223 - $63,052
-1,639 Reduced 4.18%
37,557 $1.06 Million
Q1 2022

May 16, 2022
SELL
$32.6 - $53.05 $512,374 - $833,786
-15,717 Reduced 28.62%
39,196 $1.46 Million
Q4 2021

Feb 14, 2022
BUY
$36.77 - $90.91 $108,692 - $268,729
2,956 Added 5.69%
54,913 $2.4 Million
Q3 2021

Nov 10, 2021
BUY
$41.79 - $135.3 $2.17 Million - $7.03 Million
51,957 New
51,957 $3.23 Million

Others Institutions Holding SAVA

# of Institutions
190
Shares Held
16.4M
Call Options Held
3.49M
Put Options Held
8.08M
View Full List

About CASSAVA SCIENCES INC

SAVA Quotes by TradingView
  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $108M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email